Building shared experience to advance practical application of pathway-based toxicology: Liver toxicity mode-of-action

Altex

Volumn 31, Issue 4, 2014, Pages 500-519

  Willett, Catherine ^a   Rae, Jessica Caverly ^b   Goyak, Katy O ^c   Minsavage, Gary ^c   Westmoreland, Carl ^d   Andersen, Melvin ^e   Avigan, Mark ^f   Duché, Daniel ^g   Harris, Georgina ^h   Hartung, Thomas ^h   Jaeschke, Hartmut ⁱ   Kleensang, Andre ^h   Landesmann, Brigitte ^j   Martos, Suzanne ^h   Matevia, Marilyn ^a   Toole, Colleen ^k   Rowan, Andrew ^a   Schultz, Terry ^l   Seed, Jennifer ^m   Senior, John ^f   Shah, Imran ⁿ   Subramanian, Kalyanasundaram ^o   Vinken, Mathieu ^p   Watkins, Paul ^e,q   more..

^a Humane Society of the United States   (United States)

^b DUPONT COMPANY   (United States)

^c EXXONMOBIL UPSTREAM RESEARCH COMPANY   (United States)

^d UNILEVER RESEARCH   (United Kingdom)

^e HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g L ORÉAL RECHERCHE   (France)

^h JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^j JOINT RESEARCH CENTRE   (Italy)

^k CeeTox Inc   (United States)

^l UNIVERSITY OF TENNESSEE   (United States)

^m OECD   (France)

ⁿ U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^o Strand Life Sciences ^*  (India)

^p VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^q UNIVERSITY OF NORTH CAROLINA   (United States)

more..

Author keywords

Adverse outcome pathways; In vitro toxicology; Liver toxicity; Pathways of toxicity; Systems toxicology

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CELL NUCLEUS RECEPTOR; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ADVERSE OUTCOME; CELL METABOLISM; CHEMICAL SAFETY; CLINICAL PATHWAY; CLINICAL TRIAL (TOPIC); COMPUTER MODEL; COMPUTER SIMULATION; CONFERENCE PAPER; DECISION MAKING; DRUG INDUCED DISEASE; DRUG SCREENING; ENZYME ACTIVITY; FIBROSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER METABOLISM; LIVER TOXICITY; METABOLIC CAPACITY; NONHUMAN; NONLINEAR SYSTEM; PATIENT SAFETY; POLLUTION CONTROL; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRODUCT SAFETY; QUALITY CONTROL; REPEATED DRUG DOSE; RISK ASSESSMENT; SCIENTIFIC LITERATURE; STEATOSIS; TOXIC HEPATITIS; TOXICITY TESTING; TOXICOLOGY; ADVERSE DRUG REACTION; ANIMAL; ANIMAL TESTING ALTERNATIVE; PATHOLOGY; PROCEDURES;

ANIMAL TESTING ALTERNATIVES; ANIMALS; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; TOXICITY TESTS;

EID: 84910635988     PISSN: 1868596X     EISSN: 18688551     Source Type: Journal    
DOI: 10.14573/altex.1401281     Document Type: Conference Paper

References (38)

1. Andersen, M. E. and Krewski, D. (2010). The vision of toxicity testing in the 21st century: Moving from discussion to action. Toxicol Sci 117, 17-24. http://dx. doi. org/10. 1093/toxsci/kfq188
2. Andersen, M. E., Clewell, H. J., Carmichael, P. L. and Boekelheide, K. (2011). Can case study approaches speed implementation of the NRC report: "Toxicity testing in the 21st century: a vision and a strategy?" ALTEX 28, 175-182. http://www.altex. ch/Current-issue. 50. html?iid=127&aid=1 (accessed 20. 02. 2014)
3. Andersen, M. E., McMullen, P. D. and Bhattacharya, S. (2013). Toxicogenomics for transcription factor-governed molecular pathways: moving on to roles beyond classification and prediction. Arch Toxicol 87, 7-11. http://dx. doi. org/10. 1007/s00204-012-0980-6
4. Bhattacharya, S., Zhang, Q., Charmichael, P. L. et al. (2011). Toxicity testing in the 21st century: defining new risk assessment approaches based on perturbation of intracellular toxicity pathways. PLoS ONE 6, e20887. http://dx. doi. org/10. 1371/journal. pone. 0020887
5. Boobis, A. R., Cohen, S. M., Dellarco, V. et al. (2006). IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol 36, 781-792. http://dx. doi. org/10. 1080/10408440600977677
6. Boobis, A. R., Doe, J. E., Heinrich-Hirsch, B. et al. (2008). IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit Rev Toxicol 38, 87-96. http://dx. doi. org/10. 1080/10408440701749421
7. Bottini, A. A. and Hartung, T. (2009). Food for thought on the economics of animal testing. ALTEX 26, 3-16. http://www.altex. ch/Current-issue. 50. html?iid=104&aid=1 (accessed 20. 02. 2014)
8. Cooper, S., Khatib, F., Treuille, A. et al. (2010). Predicting protein structures with a multiplayer online game. Nature 466, 756-760
9. European Commission (2005). REACH and the need for Intelligent Testing Strategies. Institute for Health and Consumer Protection, European Commission, Joint Research Centre, Ispra, Italy. http://reach-support.com/download/Intelligent%20Testing.pdf (accessed 02. 01. 2014)
10. Jaeschke, H., McGill, M. R. and Ramachandran, A. (2012a). Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. Drug Metab Rev 44, 88-106. http://dx. doi. org/10. 3109/03602532. 2011. 602688
11. Jaeschke, H., Williams, C. D., Ramachandran, A. et al. (2012b). Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity. Liver Int 32, 8-20. http://dx. doi. org/10. 1111/j. 1478-3231. 2011. 02501. x
12. Jaworska, J. and Hoffman, S. (2010). Integrated Testing Strategy (ITS)-opportunities to better use existing data and guide future testing in toxicology. ALTEX 27, 231-242. http://www.altex. ch/Current-issue. 50. html?iid=121&aid=1 (accessed 20. 02. 2014)
13. Hartung, T. (2009). Per aspirin ad astra... ATLA 37, 45-47. http://www.frame. org.uk/atla-article. php?art-id=1238&abstract=true (accessed 20. 02. 2014)
14. Hartung, T., Luechtefeld, T., Maertens, A. et al. (2013a). Integrated testing strategies for safety assessments. ALTEX 30, 3-18. http://dx. doi. org/10. 14573/altex. 2013. 1. 003
15. Hartung, T., Hoffmann, S. and Stephens, M. (2013b). Mechanistic validation. ALTEX 30, 119-130. http://dx. doi. org/10. 14573/altex. 2013. 2. 119
16. Hoffmann, S., Hothorn, L. A., Edler, L. et al. (2012). Two new approaches to improve the analysis of BALB/c 3T3 cell transformation assay data. Mutat Res 744, 36-41. http://dx. doi. org/10. 1016/j. mrgentox. 2011. 12. 002
17. Kis, E., Ioja, E., Rajnai, Z. et al. (2012). BSEP inhibition-in vitro screens to assess cholestatic potential of drugs. Toxicol In Vitro 26, 1294-1299. http://dx. doi. org/10. 1016/j. tiv. 2011. 11. 002
18. Kleensang, A., Maertens, A., Rosenberg, M. et al. (2013). Pathways of Toxicity. ALTEX 31, 53-61. http://dx. doi. org/10. 14573/altex. 1309261
19. Krewski, D., Acosta, D. Jr., Andersen, M. et al. (2010). Toxicity testing in the 21st century: a vision and a strategy. J Toxicol Environ Health B Crit Rev 13, 51-138. http://dx. doi. org/10. 1080/10937404. 2010. 483176
20. Kwekel, J. C., Burgoon, L. D., Burt, J. W. et al. (2005). A cross-species analysis of the rodent uterotrophic program: elucidation of conserved responses and targets of estrogen signaling. Physiol Genomics 23, 327-342. http://dx. doi. org/10. 1152/physiolgenomics. 00175. 2005
21. Landesmann, B., Goumenou, M., Munn, S. and Whelan, M. (2012). Description of Protoype Modes-of-Action Related to Repeated Dose Toxicity. JRC Scientific and Policy Reports 75689. http://dx. doi. org/10. 2788/71112
22. MacKay, C., Davies, M., Summerfield, V. and Maxwell, G. (2013). From pathways to people: applying the adverse outcome pathway (AOP) for skin sensitization to risk assessment. ALTEX 30, 473-786. http://dx. doi. org/10. 14573/altex. 2013. 4. 473
23. McMullen, P. D., Bhattacharya, S., Woods, C. G. et al. (2014). A map of the PPAR? transcription regulatory network for primary human hepatocytes. Chem Biol Interactions 209, 14-24. http://dx. doi. org/10. 1016/j. cbi. 2013. 11. 006
24. NRC-National Research Council (2007). Toxicity Testing in the 21st Century: A Vision and A Strategy. Washington, DC, USA: National Academies Press
25. OECD-Organization for Economic Co-operation and Development (2013). Guidance Document on Developing and Assessing Adverse Outcome Pathways. Paris, France: OECD. http://search. oecd. org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013)6&doclanguage=en (accessed 20. 02. 2014)
26. Poynard, T., Lebray, P., Ingiliz, P. et al. (2010). Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol 10, 40. http://dx. doi. org/10. 1186/1471-230X-10-40
27. Russmann, S., Kullak-Ublick, G. A. and Grattagliano, I. (2009). Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 16, 3041-3053. http://dx. doi. org/10. 2174/092986709788803097
28. Shah, I., Houck, K., Judson, R. S. et al. (2011). Using nuclear receptor activity to stratify hepatocarcinogens. PLoS ONE 6, e14584. http://dx. doi. org/10. 1371/journal. pone. 0014584
29. Stephens, M. L., Barrow, C., Andersen, M. et al. (2012). Accelerating the development of 21st-century toxicology: Outcome of a Human Toxicology Project Consortium workshop. Toxicol Sci 125, 327-334. http://dx. doi. org/10. 1093/toxsci/kfr248
30. Stephens, M. L., Andersen, M., Becker, R. A. et al. (2013). Evidence-based toxicology for the 21st century: opportunities and challenges. ALTEX 30, 74-103. http://dx. doi. org/10. 14573/altex. 2013. 1. 074
31. Sun, B., Ross, S. M., Trask, O. J. et al. (2013). Assessing dose-dependent differences in DNA-damage, p53 response and genotoxicity for quercetin and curcumin. Toxicol In Vitro 27, 1877-1887. http://dx. doi. org/10. 1016/j. tiv. 2013. 05. 015
32. Thomas, R. S., Philbert, M. A., Auerbach, S. S. et al. (2013). Incorporating new technologies into toxicity testing and risk assessment: Moving from 21st century vision to a data-driven framework. Toxicol Sci 136, 4-18. http://dx. doi. org/10. 1093/toxsci/kft178
33. US EPA (2009). EPA Issue Paper: Draft Effects-based Expert System to Predict Estrogen Receptor Binding Affinity. Federal Register docket number EPA-HQ-OPP-2009-0322 (available at regulations. gov, EPA-HQ-OPP-2009-0322-0002)
34. Vinken, M., Landesmann, B., Goumenou, M. et al. (2013). Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury. Toxicol Sci 136, 97-106. http://dx. doi. org/10. 1093/toxsci/kft177
35. Wilkening, S. and Bader, A. (2003). Influence of culture time on the expression of drug-metabolizing enzymes in primary human hepatocytes and hepatoma cell line HepG2. J Biochem Mol Toxicol 17, 207-213. http://dx. doi. org/10. 1002/jbt. 10085
36. Willett, C., Caverly Rae, J., Goyak, K. O. et al. (2014). Pathway-based toxicity: history, current approaches and liver fibrosis and steatosis as prototypes. ALTEX 31, 407-421. http://dx. doi. org/10. 14573/altex. 1401283
37. Zhang, Q. and Andersen, M. E. (2007). Dose response relationship in anti-stress gene regulatory networks. PLoS Comput Biol 3, e24. http://dx. doi. org/10. 1371/journal. pcbi. 0030024
38. Zhang, Q., Bhattacharya, S., Andersen, M. E. and Conolly, R. B. (2010).computational systems biology and dose-response modeling in relation to new directions in toxicity testing. J Toxicol Environ Health B Crit Rev 13, 253-276. http://dx. doi. org/10. 1080/10937404. 2010. 483943